According to Vision Research Reports, the global respiratory disorders treatment market size surpassed at US$ 73.11 Bn in 2021 and is projected to grow at a CAGR of 6.2% from 2022 to 2030.
According to Vision Research Reports, the global respiratory disorders treatment market size surpassed at US$ 73.11 Bn in 2021 and is projected to grow at a CAGR of 6.2% from 2022 to 2030.
The global respiratory disorders treatment market size is projected to reach US$ 125.63 billion by 2030, increase in incidence of respiratory disorders, surge in supportive care products to meet the rise in demand for treatment of respiratory disorders, entry of new players, and rise in access to healthcare are projected to drive the global respiratory disorders treatment market.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/36223
The anticipated launch of novel therapies in the global respiratory disorders treatment market such as FibroGen’s FG-3019 and Promedior’s PRM-151 for idiopathic pulmonary fibrosis (IPF) are anticipated to augment the global respiratory disorders treatment market. Increase in incorporation of premium priced therapies such as immune checkpoint inhibitor (ICI) immunotherapies into the lung cancer treatment algorithm, particularly in the first-line setting and cystic fibrosis transmembrane conductance regulator (CFTR) modulator in the cystic fibrosis (CF) market is expected to be one major drivers to the market.
North America dominated the global respiratory disorders treatment market in 2022 and the trend is anticipated to continue during the forecast period. Increase in adoption of combination drugs, availability of target therapies of all major companies in the region, introduction of new drugs such as combination drugs and cystic fibrosis transmembrane conductance regulator (CFTR) modulator, and increase in use of these drugs are projected to drive the market in North America. Asia Pacific is expected to be a highly lucrative market for respiratory disorders treatment during the forecast period. The market in the region is likely to expand at a higher CAGR from 2022 to 2030.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 73.11 billion |
| Revenue Forecast by 2030 | USD 125.63 billion |
| Growth rate from 2022 to 2030 | CAGR of 6.2% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Disease, Drug Class, Route of Administration, Distribution Channel, Region |
| Companies Covered | Mylan N.V, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Sanofi, Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries, CHIESI Farmaceutici S.p.A., Cipla, Vertex Pharmaceuticals Incorporated. |
Lung Microbiome Deploys Individual Treatment Decisions and Disease Status
The concept of lung microbiome is acquiring popularity in the respiratory disorders treatment market. Since some of the microorganisms in lungs are uninvited gatecrashers, lung microbiome helps to provide information about the status of an individual’s disease status.
Lung microbiome is as unique as an individual’s fingerprint, thus resulting in guided individual treatment decisions that help improve patient quality of life. The novel technique also has the potential to guide companies in the respiratory disorders treatment market to develop new medicines. As such, modern laboratory techniques are being deployed to gain information about the quantity and specificity of bacteria present in the sputum samples of individuals.
Several factors such as different organisms moving into the airways as well as environmental factors determine the composition of the lung microbiome among individuals. Thus, the importance of ‘friendly’ gut bacteria is gaining widespread acceptance for respiratory disorders treatment. Healthcare providers in the market of respiratory disorders treatment can increase their efficacy in lung microbiome to identify the symptoms and perhaps decipher the slow progression of respiratory infections.
Demand for Equipment in Low-income Countries to Differentiate Asthma against Self-limiting Viral Infections
Asthma is one of the most common non-communicable disease among children, with a high prevalence worldwide. This is evident since asthma dictates the highest revenue among all diseases in the respiratory disorders treatment market, where the market estimated to progress at a healthy CAGR of ~6% during the forecast period. However, challenges concerning non-availability of equipment and medications for the treatment of asthma in low-resource settings pose as a barrier for market growth. Hence, companies in the respiratory disorders treatment market should increase their production capabilities to meet the demands of healthcare facilities in low-income countries.
Sufficient availability of equipment and necessary medications helps healthcare professionals to differentiate between common respiratory conditions such as pneumonia and asthma versus self-limiting viral infections. Apart from this, there is a growing awareness about non-pharmacological interventions that are underutilized, but can ease symptoms of patients requiring respiratory disorders treatment.
Rise in Prevalence of Respiratory Diseases and Increase in Awareness about Respiratory Disorders Treatment to Drive Market
Rise in prevalence of respiratory diseases across the globe is a major factor projected to boost the growth of the global respiratory disorders treatment market. The geriatric and pediatric populations are highly susceptible to respiratory diseases due to genetics or some environmental factors including microbial exposure, exposure to passive smoking, and air pollution. This in turn increases the need of respiratory disorder treatment. According to the World Health Organization, presently, 235 million people are suffering from asthma across the globe and 338,000 deaths due to asthma were reported in 2015.
According to the Centers for Disease Control and Prevention (CDC) analysis data, prevalence of asthma was 7.8% in 2015, which increased to 7.9% in 2017 in North America alone. Asthma is one of the common lifelong chronic diseases. However, people are increasingly becoming aware about asthma and its treatment. This fuels the growth of the global respiratory disorders treatment market. The World Asthma Day is an annual event organized by the Global Initiative for Asthma (GINA) to improve asthma awareness and care around the world. The month of May is considered as National Asthma and Allergy Awareness Month to control asthma and educate people to raise awareness and improve the lives of all people.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/36223
Combination Drugs to Dominate Market
In terms of drug class, the global respiratory disorders treatment market has been divided into bronchodilators, corticosteroids, combination drugs, antibiotics, target therapy, immunotherapy, CFTR, and others. The combination drugs segment dominated the global respiratory disorders treatment market in 2022 and the trend is likely to continue during the forecast period. This can be attributed to continuous innovation in long-term therapy such as combination therapy, which provides comfort to patients and prevents symptoms.
Nasal to be Preferable Route of Administration
Based on route of administration, the global respiratory disorders treatment market has been classified into nasal, oral, and injectable. The nasal segment dominated the global respiratory disorders treatment market in 2022. It is projected to be a lucrative segment of the global respiratory disorders treatment market during the forecast period. The growth of the nasal segment is due to nasal drug therapy for respiratory disorder treatment is the preferred route of administration and medication is absorbed directly to epithelium of the lung.
Retail Pharmacies to be Key Distribution Channel
In terms of distribution channel, the global respiratory disorders treatment market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The retail pharmacies segment dominated the global respiratory disorders treatment market in terms of revenue in 2022 and the trend is anticipated to continue during the forecast period. Increase in the number of respiratory therapeutics being dispensed through retail pharmacies and rise in the number of retail pharmacies in developing countries make these pharmacies a major channel of distribution.
North America to Dominate Global Market
Geographically, the global respiratory disorders treatment market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global respiratory disorders treatment market in 2022, followed by Europe. North America accounted for major share of the global respiratory disorders treatment market in 2022, owing to the introduction of new drugs such as Vertex’s cystic fibrosis transmembrane conductance regulator (CFTR) modulator and increase in use of these drugs, and high prevalence of respiratory diseases in countries such as the U.S. The respiratory disorders treatment market in Asia Pacific is likely to expand at a higher CAGR from 2022 to 2030. Significant growth of the respiratory disorders treatment market in the region can be attributed to high prevalence of asthma and COPD and increase in demand for respiratory therapeutics.
Related Reports
- Infectious Respiratory Disease Diagnostics Market - https://www.visionresearchreports.com/infectious-respiratory-disease-diagnostics-market/39738
- Digital Respiratory Devices Market - https://www.visionresearchreports.com/digital-respiratory-devices-market/39590
- Anesthesia And Respiratory Devices Market - https://www.visionresearchreports.com/anesthesia-and-respiratory-devices-market/39423
Leading players operating in the global respiratory disorders treatment market are
-
- Mylan N.V
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis AG
- Sanofi
- Sunovion Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries
- CHIESI Farmaceutici S.p.A.
- Cipla
- Vertex Pharmaceuticals Incorporated.
- These players account for over 50% share of the global market.
Market Segmentation
By Disease
-
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Lung Cancer
- Respiratory Tract Infection
- Allergic Rhinitis
- Cystic Fibrosis (CF)
- Others
By Drug Class
-
- Bronchodilators
- Corticosteroids
- Combination Drugs
- Antibiotics
- Target Therapy
- Immunotherapy
- CFTR
- Others
By Route of Administration
-
- Oral
- Nasal
- Injectable
By Distribution Channel
-
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region
-
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/36223
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/